Respiratory toxicity of buprenorphine Results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice

Critical Care Medicine

Volumn 40, Issue 12, 2012, Pages 3215-3223

  Alhaddad, Hisham ^a   Cisternino, Salvatore ^a   Declèves, Xavier ^a   Tournier, Nicolas ^d   Schlatter, Joel ^c   Chiadmi, Fouad ^c   Risède, Patricia ^a   Smirnova, Maria ^a   Besengez, Capucine ^a   Scherrmann, Jean Michel ^a   Baud, Frédéric J ^a,b   Mégarbane, Bruno ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c HÔPITAL JEAN VERDIER   (France)

^d SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

buprenorphine; drug drug interaction; in situ brain perfusion; knockout mice; norbuprenorphine; opioid; P glycoprotein; plethysmography; respiratory depression

Indexed keywords

BUPRENORPHINE; MULTIDRUG RESISTANCE PROTEIN; NORBUPRENORPHINE; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TRANSPORT; FEMALE; IN VIVO STUDY; LUNG TOXICITY; MOUSE; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATION DEPRESSION;

ANALGESICS, OPIOID; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BUPRENORPHINE; DRUG INTERACTIONS; FEMALE; FRANCE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PLETHYSMOGRAPHY; RESPIRATORY INSUFFICIENCY;

EID: 84870253649     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318265680a     Document Type: Article

References (65)

1. Kintz P: Deaths involving buprenorphine: A compendium of French cases. Forensic Sci Int 2001; 121:65-69
2. Häkkinen M, Launiainen T, Vuori E, et al: Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 2012; 68:301-309
3. Ferrant O, Papin F, Clin B, et al: Fatal poisoning due to snorting buprenorphine and alcohol consumption. Forensic Sci Int 2011; 204:e8-11
4. Lai SH, Yao YJ, Lo DS: A survey of buprenorphine related deaths in Singapore. Forensic Sci Int 2006; 162:80-86
5. Mégarbane B, Buisine A, Jacobs F, et al: Prospective comparative assessment of buprenorphine overdose with heroin and methadone: Clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 2010; 38:403-407
6. Boyd J, Randell T, Luurila H, et al: Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003; 47:1031-1033
7. Moratti E, Kashanpour H, Lombardelli T, et al: Intravenous misuse of buprenorphine: Characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig 2010; 30(Suppl 1):3-11
8. Lavie E, Fatséas M, Denis C, et al: Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. Drug Alcohol Depend 2009; 99:338-344
9. Shook JE, Watkins WD, Camporesi EM: Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. Am Rev Respir Dis 1990; 142:895-909
10. Tournier N, Declèves X, Saubaméa B, et al: Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: Implications for neuropsychopharmacology. Curr Pharm Des 2011; 17:2829-2842
11. Walsh SL, Preston KL, Stitzer ML, et al: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-580
12. Yassen A, Olofsen E, Romberg R, et al: Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81:50-58
13. Cowan A, Doxey JC, Harry EJ: The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977; 60:547-554
14. Dahan A, Yassen A, Bijl H, et al: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94:825-834
15. Picard N, Cresteil T, Djebli N, et al: In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos 2005; 33:689-695
16. Nagar S, Remmel RP, Hebbel RP, et al: Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos 2004; 32:98-104
17. Ohtani M, Kotaki H, Sawada Y, et al: Comparative analysis of buprenorphine-and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272:505-510
18. Mégarbane B, Marie N, Pirnay S, et al: Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 2006; 212:256-267
19. Gueye PN, Borron SW, Risède P, et al: Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol Sci 2001; 62:148-154
20. Nielsen S, Taylor DA: The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend 2005; 79:95-101
21. Tournier N, Chevillard L, Megarbane B, et al: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 2010; 13:905-915
22. Bartlett D Jr, Tenney SM: Control of breathing in experimental anemia. Respir Physiol 1970; 10:384-395
23. Bonora M, Bernaudin JF, Guernier C, et al: Ventilatory responses to hypercapnia and hypoxia in conscious cystic fibrosis knockout mice Cftr-/-. Pediatr Res 2004; 55:738-746
24. Dagenais C, Rousselle C, Pollack GM, et al: Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein- deficient mice. J Cereb Blood Flow Metab 2000; 20:381-386
25. Papoutsis II, Nikolaou PD, Athanaselis SA, et al: Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. J Pharm Biomed Anal 2011; 54:588-591
26. Gopal S, Tzeng TB, Cowan A: Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma. Eur J Pharm Biopharm 2001; 51:147-151
27. Ohtani M, Shibuya F, Kotaki H, et al: Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in human plasma by gas chromatography-chemical ionization mass spectrometry. J Chromatogr 1989; 487:469-475
28. Cattelotte J, André P, Ouellet M, et al: In situ mouse carotid perfusion model: Glucose and cholesterol transport in the eye and brain. J Cereb Blood Flow Metab 2008; 28:1449-1459
29. Lizasoain I, Leza JC, Lorenzo P: Buprenorphine: Bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 1991; 22:297-300
30. Hreiche R, Mégarbane B, Pirnay S, et al: Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression. Toxicol Appl Pharmacol 2006; 217:352-362
31. Gonzalez O, Colombo T, De Fusco M, et al: Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 1995; 36:335-340
32. Colombo T, Gonzalez Paz O, D'Incalci M: Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73:866-871
33. Tallarida R, Murray RB: Area under a curve: Simpson's rule and trapezoidal rule. In: Manual of Pharmacologic Calculations with Computer Programs. Tallarida R, Murray RB (Eds). New York, NY, Springer-Verlag, 1981, pp 47-49
34. Chevillard L, Mégarbane B, Risède P, et al: Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol Lett 2009; 191:327-340
35. Selley DE, Sim LJ, Xiao R, et al: Mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 1997; 51:87-96
36. Huang P, Kehner GB, Cowan A, et al: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297:688-695
37. Ohtani M, Kotaki H, Nishitateno K, et al: Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281:428-433
38. Thiebaut F, Tsuruo T, Hamada H, et al: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-7738
39. Croop JM, Raymond M, Haber D, et al: The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9:1346-1350
40. Gros P, Ben Neriah YB, Croop JM, et al: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323:728-731
41. Devault A, Gros P: Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990; 10:1652-1663
42. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427
43. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993; 72:3553-3563
44. Archinal-Mattheis A, Rzepka RW, Watanabe T, et al: Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 1995; 7:603-610
45. Bourasset F, Cisternino S, Temsamani J, et al: Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem 2003; 86:1564-1567
46. Cisternino S, Bourasset F, Archimbaud Y, et al: Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003; 138:1367-1375
47. Müller M, Jansen PL: Molecular aspects of hepatobiliary transport. Am J Physiol 1997; 272:G1285-G1303
48. Miller DS, Fricker G, Drewe J: p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 1997; 282:440-444
49. Wandel C, Kim RB, Kajiji S, et al: P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res 1999; 59:3944-3948
50. Song S, Suzuki H, Kawai R, et al: Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 1998; 26:1128-1133
51. Achira M, Suzuki H, Ito K, et al: Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1999; 1:E18
52. Kharasch ED, Hoffer C, Whittington D, et al: Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74:543-554
53. Kharasch ED, Hoffer C, Altuntas TG, et al: Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 2004; 44:224-233
54. Zhou SF: Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38:802-832
55. Mayer U, Wagenaar E, Dorobek B, et al: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100:2430-2436
56. Zong J, Pollack GM: Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm Res 2000; 17:749-753
57. Letrent SP, Pollack GM, Brouwer KR, et al: Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 1999; 27:827-834
58. Thompson SJ, Koszdin K, Bernards CM: Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92:1392-1399
59. Megarbane B, Pirnay S, Borron SW, et al: Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol Lett 2005; 157:211-219
60. Nekhayeva IA, Nanovskaya TN, Hankins GD, et al: Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel. Am J Perinatol 2006; 23:423-430
61. Hassan HE, Myers AL, Coop A, et al: Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: In vitro and in vivo evaluation. J Pharm Sci 2009; 98:4928-4940
62. Suzuki T, Zaima C, Moriki Y, et al: P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. J Drug Target 2007; 15:67-74
63. Sadeque AJ, Wandel C, He H, et al: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68:231-237
64. Skarke C, Jarrar M, Erb K, et al: Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74:303-311
65. Drewe J, Ball HA, Beglinger C, et al: Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000; 50:237-246